LIST: East Texas hospitals get Fall 2024 safety ratings

TYLER, Texas ( KETK ) – 13 East Texas hospitals have been given "A" safety ratings for the Fall of 2024, that's up two from 11 A ratings in the Spring of 2024 .

UPDATE: Country singer Sundance Head released from Tyler hospital after shooting

The ratings are reported twice a year by the Leapfrog Group, a nonprofit that studies hospitals from across the country. They study hospitals for their amount of errors, injuries, accidents and infections and rate them on a scale from A to F, with A being the safest.

KETK has put together the following list of Fall 2024 ratings for East Texas hospitals:

CHI St. Luke's Health Memorial (Lufkin) – B

CHI St. Luke's Health Memorial Livingston – A

CHRISTUS Good Shepherd Medical Center – Longview – A

CHRISTUS Good Shepherd Medical Center – Marshall – A (up from B in Spring 2023)

CHRISTUS Mother Frances Hospital – Sulphur Springs – A

CHRISTUS Mother Frances Hospital – Tyler – A

CHRISTUS St. Michael Health System – A

CHRISTUS St. Michael Hospital – Atlanta – A

Longview Regional Medical Center – A

Nacogdoches Medical Center – C

Nacogdoches Memorial Hospital – D

Palestine Regional Medical Center-East – B

Titus Regional Medical Center – B

UT Health Athens – A (up from B in Spring 2024)

UT Health Henderson – A

UT Health Jacksonville – A (up from B in Spring 2024)

UT Health Tyler – A

Wadley Regional Medical Center (Texarkana) – C

Woodland Heights Medical Center (Lufkin) – B

To see how these hospitals compare to the rest of Texas, visit the Leapfrog Group online .

For the latest news, weather, sports, and streaming video, head to KETK.com | FOX51.com.

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings. While

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the process of building out the infrastructure it needs to administer and manufacture its first gene therapy to get approval, which is called Casgevy. The odds are good that the medicine will make for a slow burn rather than a windfall profit, as the proceeds will be split with Vertex Pharmaceuticals, which will take the larger share of the pie.